Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry

  • Barclay W
  • Long J
  • Wright E
  • et al.
N/ACitations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Emerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs. The former was the only available intervention when the current unprecedented Ebolavirus (EBOV) outbreak in West Africa began. Prior to this, the development of EBOV vaccines and anti-viral therapies required time and resources that were not available. Therefore, focus has turned to re-purposing of existing, licenced medicines that may limit the morbidity and mortality rates of EBOV and could be used immediately. Here we test three such medicines and measure their ability to inhibit pseudotype viruses (PVs) of two EBOV species, Marburg virus (MARV) and avian influenza H5 (FLU-H5). We confirm the ability of chloroquine (CQ) to inhibit viral entry in a pH specific manner. The commonly used proton pump inhibitors, Omeprazole and Esomeprazole were also able to inhibit entry of all PVs tested but at higher drug concentrations than may be achieved in vivo. We propose CQ as a priority candidate to consider for treatment of EBOV. © 2015 Long J et al.

Cite

CITATION STYLE

APA

Barclay, W. a, Long, J. a, Wright, E. b, Molesti, E. c, & Temperton, N. c. (2015). Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research, 4. https://doi.org/10.12688/f1000research.6085.2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free